Tesamorelin

Tesamorelin is studied for its effects on growth-hormone signaling and related metabolic processes. Research commonly examines its relationship with growth-hormone release, body-composition pathways, and energy metabolism.

Technical Research Details
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It consists of a modified peptide sequence that has been studied for its receptor interactions, structural characteristics, and enzymatic stability.
The compound has been examined in preclinical and laboratory research involving GHRH receptor activity, receptor-mediated signaling, and comparative studies of modified peptide analogs. Alpha Tides PNW supplies Tesamorelin as a lyophilized research compound in 10MG and 20MG vial sizes for laboratory research use.

Product Information

Form: Lyophilized powder
Contents: 10MG or 20MG per vial (by selected size)
Sequence: GHRH(1-44)-NH2 analog with trans-3-hexenoic acid modification
Molecular weight: 5135.8 Da
Storage: −20°C lyophilized; 2–8°C after reconstitution

Purity
99.87%
Research Applications

GHRH receptor research: Studies examining receptor binding and receptor-mediated signaling pathways.
Peptide pharmacology: Comparative research involving modified peptide analogs and endogenous GHRH sequences.
Cellular signaling research: Investigation of intracellular signaling associated with GHRH receptor activity.
Compound stability studies: Research examining structural modifications and their relationship to enzymatic stability.
Comparative pharmacology: Studies comparing receptor interactions and signaling characteristics among GHRH-related compounds.
Peptide structure research: Investigation of structural features and their influence on compound behavior in laboratory models.

Research Notes
Tesamorelin has been studied as a modified GHRH analog in research examining receptor interactions, peptide pharmacology, and intracellular signaling pathways. Its structural characteristics have also been evaluated in relation to enzymatic stability and compound behavior when compared with endogenous GHRH sequences.
The compound has been included in preclinical and laboratory studies investigating GHRH receptor pharmacology and the broader characteristics of modified peptide analogs. Its established research history makes it a useful reference material for comparative studies involving peptide structure, receptor activity, and signaling mechanisms.
Batch-specific product information and laboratory documentation are available through the applicable Certificate of Analysis.

Frequently Asked Questions
How does Tesamorelin differ from CJC-1295?
Both are GHRH analogs but with different structural modifications. Tesamorelin uses a trans-3-hexenoic acid modification for DPP-IV protection and retains the full 44-amino acid GHRH sequence. CJC-1295 typically uses a drug affinity complex (DAC) modification for albumin binding, extending half-life further and producing a more sustained GH release pattern. The two are sometimes compared in GHRH receptor pharmacology studies examining GH pulse kinetics.
What research has been published on Tesamorelin?
Tesamorelin has an established preclinical and pharmacological research literature examining its GHRH receptor activity, visceral fat and lipid metabolism effects, and cognitive research applications in aging models. It remains an active reference compound in GH/IGF-1 axis research.
How should Tesamorelin be stored?
Store lyophilized vials at −20°C before reconstitution. After reconstitution with bacteriostatic water, refrigerate at 2–8°C and use within 28 days.

Tesamorelin is intended strictly for laboratory research by qualified professionals. It is not FDA approved for general use and is not for human or animal administration. By purchasing, the buyer confirms the product will be used solely for in vitro research in compliance with all applicable laws and regulations.